2 Pekeris Street
86 articles with CollPlant
CollPlant today announced financial results for the second quarter ended June 30, 2018 and provided an update on the Company's business developments.
CollPlant today announced that it will be featured as a presenting company at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co. LLC.
CollPlant's American Depositary Shares to continue trading on the Nasdaq Capital Market
CollPlant announced the appointment of Dr. Wolfgang Ruttenstorfer to its board of directors, increasing the board to seven members.
CollPlant Receives Research and Development Project Approval From the Israel Innovation Authority to Advance its Collagen-based BioInk for 3D Printing of Tissues and Organs
CollPlant announced that it has received grant approval from the Israel Innovation Authority (IIA)
CollPlant Appoints Professor Shay Soker from Wake Forest Institute for Regenerative Medicine to its Scientific Advisory Board
Appointment of Shay Soker, Professor at the Wake Forest Institute for Regenerative Medicine (WFIRM), to its Scientific Advisory Board.
CollPlant is a regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue repair products
CollPlant announced that it has completed the third and final closing of the investment agreement with Alpha Capital Anstalt.
CollPlant announced the appointment of Revital Mandil-Levin, PhD, MBA as Chief Business Development Officer, effective immediately.
CollPlant is a regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue repair products.
CollPlant Joins ReMDO's Advanced Biomanufacturing Initiative for Development of a Universal BioInk for 3D Bioprinting of Tissues and Organs
CollPlant announced that it is part of ReMDO's advanced biomanufacturing initiative for the development of a universal BioInk with tunable properties for 3D bioprinting of tissues and organs.
Trading commenced on Wednesday, January 31, 2018 under the ticker symbol "CLGN".
CollPlant announced the appointment of David Tsur to the position of Chairman of the Board of Directors, effective immediately.
CollPlant announced that it has received an additional order, totaling hundreds of thousands of dollars, for the supply of its collagen and biological ink.
CollPlant Expands European Sales Network: The Company Has Signed a Distribution Agreement in Greece and Cyprus for Vergenix FG for Treatment of Acute and Chronic Wounds and Surgical Cuts
Under the terms of the agreement, the distributor undertook to make the first order for the product when signing the agreement, in an amount that is not material to the Company.
Vote of Confidence in CollPlant: Completion of Agreement for Immediate Investment of USD 1.1 Million From Ami Sagi, One of the Company's Largest Shareholders
CollPlant announces that it has signed a private restricted investment agreement with Mr. Ami Sagi, one of the Company's largest shareholders.
CollPlant In Advanced Negotiations For US Private Placement Of USD 5.0 Million; Agreement Includes Plan For NASDAQ Uplisting